drugset
drugset / Trial / NCT05234775

Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product

NCT05234775 ↗

Phase 3 Completed 22 enrolled LIB Therapeutics LLC Medpace, Inc. · collab
Non-randomizedCrossoverOpen-labelTreatment

Summary

To compare the pharmacokinetics (PK), and pharmacodynamics (PD) of single subcutaneous (SC) doses of 300 mg LIB003 Process 1 (P1) and Process 2 (P2) drug product in subjects with or without statin therapy

Timeline

Start
2022-01-28
Primary completion
2022-06-30
Completion
2022-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject lerodalcibep Protein / enzyme biologic 300 mg Subcutaneous

Indications

hyperlipidemia